In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Rigel Pharmaceuticals, Inc.

http://www.rigel.com

Latest From Rigel Pharmaceuticals, Inc.

Execs On The Move: April 2022

An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.

Commercial Companies

Will Yabao Help Lupin’s Attempts To Scale The Great Wall?

With the Yabao partnership, Lupin builds on a toehold gained through the Foncoo tie-up as it attempts to scale the market behind the Great Wall of China. Scrip takes a look at possible approaches and potential of the partnership

Commercial Business Strategies

Axsome Is Latest To Falter With Technology For Unlocking Meloxicam’s Analgesic Potential

Axsome’s CRL was not the first from the US FDA for the nearly insoluble NSAID as sponsors try different technologies for delivering its pain relief quickly.

Complete Response Letters Manufacturing

Lupin Lines Up Rival To Teva’s Austedo – But Not Until 2033

Lupin will be able to launch a deutetrabenazine generic rival to Teva’s Austedo brand in the US from 2033, following a settlement agreement between the two firms. However, Aurobindo is continuing to fight a patent-infringement suit with the Israeli firm.

Intellectual Property Legal Issues
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
UsernamePublicRestriction

Register